While the most consistent and pronounced effects were observed following BRD4 knockdown, loss of BRD2 and BRD3 also inhibited LNCaP cell growth, suggesting that all three BET family proteins contribute to the potent growth responses to BET inhibitors observed in prostate cancer cell lines. The gene discussed is BRD4; the disease is prostate carcinoma.